Clearmind Medicine Achieves Major Milestone in Clinical Trials
Clearmind Medicine Inc. (NASDAQ: CMND), a pioneering clinical-stage biotech entity, is thrilled to announce the recent approval from an Institutional Review Board (IRB) concerning its Phase I/IIa clinical trial aimed at alleviating alcohol use disorder (AUD). This achievement signifies an important step forward in the company's mission to develop innovative therapies derived from psychedelics to tackle challenging health issues.
Significance of IRB Approval
The approval from the IRB at one of the clinical sites in the United States propels Clearmind further into its research agenda. The Phase I/IIa trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, a treatment engineered from MEAI (5-methoxy-2-aminoindane), specifically designed for those grappling with alcohol use disorders.
Clinical Trial Overview
This multinational, multi-center study not only embraces collaboration with esteemed institutions such as Johns Hopkins University in Maryland but also engages Yale School of Medicine in Connecticut and IMCA Center in Israel. With the necessary FDA approval for the Investigational New Drug (IND) application already established, the groundwork is laid for this significant trial.
Addressing a Global Health Concern
Dr. Adi Zuloff-Shani, the CEO of Clearmind Medicine, articulated the significance of this advancement, stating, "The IRB's approval is a pivotal milestone towards launching our clinical trial aimed at alcohol use disorder. Together with approvals from the IMCA, this represents our second authorized site, allowing us to inch closer to providing assistance to those adversely affected by alcohol addiction, which remains a pressing health challenge globally." Alcohol addiction impacts many lives, and this research is crucial in finding effective treatments. As AUD is recognized as the most prevalent substance use disorder among individuals aged 12 and older, the implications of this trial could be groundbreaking.
Primary Focus of the Study
The central aim of the trial, scheduled as a single and multiple dose study, is to determine the tolerable dose of CMND-100 while ensuring the safety and assessing the pharmacokinetics and pharmacodynamics involved. This information is vital as the scientific community continues to explore potential solutions for alcohol addiction.
Continuing Innovation at Clearmind
Clearmind Medicine prides itself on its innovative spirit, which is reflected in its extensive intellectual property portfolio that encompasses nineteen patent families, including 29 granted patents. The company remains dedicated to seeking new patents that could enhance its offerings and address the urgent health issues faced by many.
Investing in the Future
With its shares actively traded on NASDAQ under the ticker symbol "CMND" and on Frankfurt Exchange labeled as "CWY0," Clearmind Medicine is positioned firmly in the market. Investors and stakeholders are encouraged to stay updated with the company's developments through regular communications.
Company Contact Information
For further inquiries, Clearmind thoroughly welcomes questions and discussions. Interested parties may reach out via email at invest@clearmindmedicine.com or contact them directly at (604) 260-1566.
Frequently Asked Questions
What is the purpose of the CMND-100 clinical trial?
The CMND-100 clinical trial focuses on assessing safety, tolerability, and pharmacokinetics for patients with alcohol use disorder (AUD).
What does IRB approval signify for Clearmind Medicine?
IRB approval indicates that the trial has met ethical and safety standards, allowing it to commence at designated clinical sites.
How does CMND-100 work against alcohol use disorder?
CMND-100 is based on MEAI, which is designed to target and alleviate symptoms associated with alcohol use disorders.
Where will the clinical trials take place?
The trials are set to occur at multiple sites, including Johns Hopkins University, Yale School of Medicine, and also at IMCA Center in Israel.
What is Clearmind Medicine's focus as a biotech company?
Clearmind Medicine focuses on developing psychedelic-derived therapeutics aimed at addressing under-treated health conditions, particularly AUD.
